The Real-World Impact of CAR T-Cell Therapy in Large B-Cell Lymphoma : Episode 8

News

Video

February 20, 2024

Bridging Therapy With CAR T-Cell Therapy in LBCL

Author(s):

Caron Jacobson, MD,Miguel-Angel Perales, MD

Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, discuss different uses for CAR T-cell therapy, particularly a trial in which a CAR T-Cell therapy is being evaluated in MRD-positive patients treated with chemotherapy.

EP: 1.The Expanding Utility of CAR T-Cell Therapy in LBCL

EP: 2.Sequencing With CAR T-Cell Therapy for LBCL

EP: 3.CAR T-Cell Therapy as a Second-Line Treatment for LBCL

EP: 4.Understanding Malignancy Risks With the Use of CAR T-cell Therapies

EP: 5.Real World Findings for Liso-Cel in LBCL From the Cell Therapy Consortium

EP: 6.Expert Perspective on Real-World Follow-Up Analyses of Liso-Cel in LBCL

EP: 7.The Impact of Real-World Analyses in the Utilization of CAR T-Cell Therapy in LBCL

Now Viewing

EP: 8.Bridging Therapy With CAR T-Cell Therapy in LBCL

EP: 9.The Future of CAR T-Cell Therapy in LBCL

EP: 10.Back to the Bench: Exploring the Potential of CAR T-Cell Therapy in Oncology

Related Content

November 15th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

November 14th 2024

FDA Approves Nilotinib Tablets Without Mealtime Restrictions for CML

November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Jennifer Amengual, MD, Herbert Irving Assistant Professor of Medicine, Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center

November 13th 2024

Real-World Experience With CAR T Varies From Trials in DLBCL

Revumenib in NPM1+ R/R AML | Image Credit: © LASZLO– stock.adobe.com

November 12th 2024

Revumenib Meets CR/CRh End Point in NPM1+ R/R AML